Cullinan Therapeutics (CGEM)
Develops bispecific T-cell engagers for autoimmune disease and cancer through a hub-and-spoke drug-development model.
$21.69
vs last close+0.34 (+1.59%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 111.27% | 71.61M shares | |
|---|---|---|---|
| 193 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.88% | 1.21M shares | |
| 6 holders · as of Sep 10, 2026 | |||
| Adds to | 113.15% | ||
64.35M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 113.15%; nothing is left for Other.
13F, as of Jun 30, 2026
193 holders · 71.61M shares · 35 new positions · 119 increased · 46 reduced · 21 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Bioimpact Capital LLC | 9.73M | 15.12% | +2.08M | Aug 14, 2026 |
| LYNX1 Capital Management LP | 8.96M | 13.93% | 0 | Aug 13, 2026 |
| BVF Inc/IL | 5.75M | 8.94% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 5.23M | 8.13% | +782.8K | Aug 7, 2026 |
| Price T Rowe Associates Inc /MD/ | 3.83M | 5.95% | +1.80M | Aug 14, 2026 |
| State Street Corp | 3.67M | 5.70% | +1.12M | Aug 7, 2026 |
| Kynam Capital Management, LP | 3.11M | 4.84% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.61M | 4.06% | +131.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| LYNX1 Capital Management LP | 9.80% | 5.77M | 13G | Nov 14, 2025 |
| BlackRock, Inc. | 7.50% | 4.34M | Nov 8, 2024 | |
| T. Rowe Price Associates, Inc. | 6.20% | 3.83M | 13G | Aug 14, 2026 |
| State Street Corporation | 6.00% | 3.67M | 13G | Aug 7, 2026 |
| Biotechnology Value Fund L P | 5.80% | 3.55M | 13G | May 15, 2026 |
| Kynam Capital Management, LP | 5.27% | 3.11M | 13G | Mar 4, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 8,000 | $21.57 | 158,844 |
| Aug 13, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 30,000 | $20.26 | 162,844 |
| Jul 6, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 8,000 | $17.82 | 162,844 |
| May 5, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale · 2 lots | 8,000 | $14.62 | 166,844 |
| Mar 5, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 8,000 | $15.68 | 170,844 |
| Feb 25, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 1,780 | $14.14 | 174,844 |
| Feb 24, 2026 | Jacquelyn L. Sumerofficer: Chief Legal Officer | Sale | 3,601 | $14.47 | 128,089 |
| Feb 24, 2026 | Jeffrey Alan Jonesofficer: Chief Medical Officer | Sale | 4,582 | $14.47 | 159,968 |
| Feb 24, 2026 | Nadim Ahmeddirector, officer: President and CEO | Sale | 13,515 | $14.47 | 390,803 |
| Feb 24, 2026 | Jennifer Michaelsonofficer: Chief Scientific Officer | Sale | 3,601 | $14.47 | 176,624 |
House and Senate disclosures
Not reported.